Printed from Voxsanity (voxsanity.com.au) — NCT06139783 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
Back to Ovarian Cancer
Ovarian Cancer Trial, Not Yet Recruiting
NCT06139783
voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice
Who may and may not be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who may be able to join
- Women aged 18 or older.
- People diagnosed with high-grade serous or endometrioid ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
- People who are willing and able to sign a written consent form.
- People with a good general level of functioning, able to carry out normal daily activities with little or no limitation (confirm with trial site what this means for individual circumstances).
- People whose cancer is at an advanced stage (Stage III or IV, as classified by the international gynaecology staging system).
- People with a life expectancy of at least 6 months.
- People who are on a maintenance treatment called a PARPi (a type of targeted cancer drug) after responding to their first course of platinum-based chemotherapy, and who started that treatment at least 4 weeks before signing the consent form.
- People who are clinically stable and expected to remain on their current treatment for the full duration of the exercise program.
- People who are willing to provide a tumour tissue sample from a previous biopsy or surgery (if one is available).
- People who have enough ability to use digital technology, as assessed by the trial team.
- People who are able and willing to follow the study plan for the full duration of the study, including all follow-up steps.
- People whose recent blood test results (taken within 28 days of enrolling) meet all of the following levels (confirm specific values with trial site):
- Platelet count of 100 × 10⁹/L or higher.
- Neutrophil count (a type of white blood cell) of at least 1,500 per mm³.
- Haemoglobin (a measure of red blood cells) of at least 9 g/dL or 5.6 mmol/L.
- Liver enzyme levels (AST and ALT) within an acceptable range relative to normal limits, with a higher allowance for people with known liver spread.
- Bilirubin (a liver-related substance in the blood) within an acceptable range relative to normal limits.
- A specific bilirubin range where a dose adjustment of the study drug to 200 mg daily may apply (confirm with trial site).
- Kidney function within an acceptable range, based on either a creatinine blood test or a kidney filtration rate calculation.
Who may not be able to join
Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.
- People whose ovarian cancer has come back after a previous treatment (recurrent ovarian cancer).
- People with a serious, non-healing wound, ulcer, or bone fracture.
- People with active bleeding or a condition that carries a high risk of bleeding, such as a known bleeding disorder.
- People with a disease affecting the brain or central nervous system.
- People with a history of significant heart problems in the 6 months before enrolling, including any of the following:
- Moderate to severe heart failure.
- Certain types of serious, uncontrolled abnormal heart rhythms.
- A heart attack or heart disease caused by reduced blood flow.
- Significant heart valve disease.
- A stroke caused by either blocked or burst blood vessels.
- Blood clots in the veins or arteries.
- Disease affecting the blood vessels in the legs or arms.
- Aortic aneurysm or aortic dissection (serious conditions affecting the body's main artery).
- People with uncontrolled high blood pressure, confirmed by two separate readings at least five minutes apart (systolic of 140 or higher, or diastolic of 90 or higher).
- People who need fluid drained from their body once a month or more, or who have had 500 mL or more of fluid drained within 4 weeks of the expected start of the exercise program.
- People who have an active infection or a fever of 38.5°C or higher within 7 days before the program starts that requires antibiotic treatment (except for uncomplicated urinary tract infections).
- People who have had a major surgical procedure within 3 weeks before screening, or who have surgery planned during the program.
- People with a known heart electrical conduction abnormality (prolonged QT interval), a known inherited condition causing prolonged QT, or who are taking a medication known to cause this type of heart rhythm change.
- People who have received a blood transfusion or certain blood-stimulating medications within 4 weeks before the exercise program is due to start.
- People with a pre-existing chronic lung condition, lung disease caused by cancer spread, fluid around the lungs, or lung inflammation.
- People with widespread bone disease unrelated to cancer, cancer that has spread to the long bones of the body, or other painful bone involvement from cancer.
- People with significant nerve damage in the hands or feet that could interfere with taking part in the exercise program, as assessed by the trial team.
- People who are pregnant, breastfeeding, or planning to become pregnant during the program.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.
Contact this trial
Principal Investigator: Alfonso Cortés, MD, Hospital Universitario Ramón y Cajal
Phone: +34 912878564
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Status
Not Yet Recruiting
Phase
Not Applicable
Sponsor
Oncare Madrid
Registry
ClinicalTrials.gov
Start date
1 May 2026
Est. completion
1 January 2027
Where this trial is recruiting
🇪🇸 Spain
Primary endpoints
To evaluate the feasibility (adherence) of a supervised physical exercise program in ovarian cancer patients on PARPi treatment.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.